Lung Cancer Oncotherapy through Novel Modalities: Gas Plasma and Nanoparticle Technologies

Abstract

Cold atmospheric pressure plasma (CAP) is emerging as new healthcare technology and it has a high potential through physical and chemical effects for cancer treatment. Recently, CAP, plasma activated liquid (PAL), and nanomaterial have been significant advances in oncotherapy. Reactive oxygen-nitrogen species (RONS), electrical field, and other agents generated by CAP interact with cells and induce selective responses between the malignant and normal cells. Nanomedicine enhances therapeutic effectiveness and decreases the side effects of traditional treatments due to their target delivery and dispersion in tumor tissue. There are various nanocarriers (NCs) which based on their properties can be used for the delivery of different agents. The combination of gas plasma and nanomaterials technologies is a new multimodal treatment in cancer treatment, therefore, is expected that the conjunction of these technologies addresses many of the oncology challenges. This chapter provides a framework for current research of NC and gas plasma therapies for lung cancer. Herein, we focus on the application of gas plasmas and nanotechnology to drug and gene delivery and highlight several outcomes of its. The types and features of the mentioned therapeutics strategy as novel classes for treating lung cancer individually and synergistic were examined.

Plasma‐activated medium induces apoptosis in chemotherapy‐resistant ovarian cancer cells: High selectivity and synergy with carboplatin

“…CAP helps reduce the resistance of cancer cells to chemotherapy drugs, [ 56,57 ] for example, TRAIL‐resistant colorectal cancer cells. [ 58 ] Here, we examined one of the most important resistance mechanics. We found that all of the combination treatments with PAM restore CAR sensitivity in resistant A2780 CP and SKOV‐3 OC cells.…”